I am a Partner and Evidence Generation Lead in the Health Analytics team, as well as a medical doctor and epidemiologist with a clinical background in nephrology and public health. I have more than 10 years’ experience in academia and industry designing and executing scientific studies using real world health data, and developing advanced analytics solutions. My previous roles have included Clinical Lead (Stroke) for the National Cardiovascular Intelligence Network. I am Honorary Senior Clinical Lecturer at King’s College London, where I work on research into machine learning analytics using large health databases. I’m an author on more than 40 peer reviewed publications and I sit on the editorial board of the Drug Safety journal.

Xabier García de Albéniz, MD, PhD is Senior Director, Epidemiology, at RTI Health Solutions. Dr. García de Albéniz provides oncology and methodologic expertise in epidemiology at RTI HS and has a background in oncology, epidemiology, and biostatistics. Dr. García de Albéniz trained as a clinical oncologist in Barcelona while pursuing a Master’s degree in biostatistics and has worked for several years within the Program on Causal Inference, Department of Epidemiology at the Harvard T.H. Chan School of Public Health, where he maintains an affiliation as a collaborator of the CAUSALab. His areas of expertise include the use of cutting-edge causal inference methods to design and analyze studies that use real-world data.

Jesper Hallas, MD, DrMedSci, is Professor of Clinical Pharmacology at the University of Southern Denmark. He established pharmacoepidemiology as a research discipline in Denmark in the late 1980s and has contributed substantially to studies of adverse drug effects, methodological development, and the use of large-scale real-world data to identify unsuspected drug–outcome associations. He has published more than 500 peer-reviewed papers, supervised over 35 PhD theses, and served as President of the International Society for Pharmacoepidemiology.

Professor Deborah Layton FRPharmS, FISPE, FRPharmS PhD is a UK-based pharmacoepidemiologist and pharmacovigilance expert with over two decades’ experience in medicines safety, real-world evidence and regulatory decision support. She is Principal Drug Safety Lead at Lane, Clarke and Peacock (LCP) LLP and founder of PEPI Consultancy Ltd, providing senior advisory input on post-authorisation safety studies, risk management and evidence governance. She is an honorary professor at University of Hertfordshire, is widely published and has previously held executive leadership roles, with responsibility for oversight of large, complex post-marketing safety programmes using routine healthcare data.

Dr. Margulis is a Senior Director of Epidemiology at RTI Health Solutions. She studied Medicine and completed a Pediatrics residency in Buenos Aires, completed her doctoral studies in Epidemiology at Harvard School of Public Health in Boston and did post-doctoral training at the US Food and Drug Administration. Dr. Margulis has led several multidatabase postauthorization safety studies conducted at the request of regulatory agencies. Her main research interest is pharmacoepidemiology; much of her work focuses on the safety of medical products in pregnancy. Dr. Margulis is an Associate Editor for the journal Pharmacoepidemiology and Drug Safety and serves in the Board of Directors of the International Society for Pharmacoepidemiology.

Saad Shakir is a pharmacoepidemiologist and drug safety physician. He has worked in the fields of pharmacovigilance, pharmacoepidemiology and risk management for 30 years, initially at the UK Regulatory Authority, then the international pharmaceutical industry and as the Director of the Drug Safety Research Unit (DSRU) in Southampton. He has led many important drug safety studies and has worked and advised on many drug safety issues including product withdrawals, major restrictions and important safety hazards. Saad will start a new stage in his career as a consultant in Pharmacovigilance and Pharmacoepidemiology on 1 June 2025